TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of “Moderate Buy” from Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $122.70.

Several analysts have weighed in on the stock. Canaccord Genuity Group decreased their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Wednesday, December 11th. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Piper Sandler lowered their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd.

Insider Activity

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the transaction, the insider now owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now owns 732 shares in the company, valued at approximately $61,158.60. This trade represents a 90.22 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds have recently bought and sold shares of TMDX. USA Financial Formulas acquired a new position in shares of TransMedics Group in the 3rd quarter valued at $55,000. Quarry LP grew its stake in TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after acquiring an additional 312 shares during the period. National Bank of Canada FI grew its stake in TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after acquiring an additional 262 shares during the period. Farther Finance Advisors LLC grew its stake in TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after acquiring an additional 316 shares during the period. Finally, Sachetta LLC acquired a new position in TransMedics Group in the fourth quarter valued at about $40,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $60.82 on Friday. The business’s fifty day moving average price is $69.04 and its two-hundred day moving average price is $115.58. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of 64.70 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The firm had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.12) EPS. As a group, analysts predict that TransMedics Group will post 1 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.